No Data
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating
Express News | Solid Biosciences Doses First Participant in Phase 3 Impact Duchenne Clinical Trial Evaluating Sgt-003 in Duchenne Muscular Dystrophy
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
Express News | Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
FDA Said to Have Named Katherine Szarama as Acting CBER Chief
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)